• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.干燥综合征患者的死亡率、危险因素及病因:队列研究的系统评价与荟萃分析
Rheumatology (Oxford). 2016 Mar;55(3):450-60. doi: 10.1093/rheumatology/kev354. Epub 2015 Sep 27.
2
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.对早期预后不良或晚期霍奇金淋巴瘤患者,比较包括强化BEACOPP方案的一线化疗与包括ABVD方案的化疗。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
5
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
6
Exercise-based cardiac rehabilitation for coronary heart disease.基于运动的冠心病心脏康复。
Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.丙型肝炎病毒相关混合性冷球蛋白血症的治疗
Cochrane Database Syst Rev. 2018 May 7;5(5):CD011403. doi: 10.1002/14651858.CD011403.pub2.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.

引用本文的文献

1
[Sjögren disease complicated by primary breast lymphoma: A case report].干燥综合征合并原发性乳腺淋巴瘤:一例报告
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Aug 18;57(4):808-811. doi: 10.19723/j.issn.1671-167X.2025.04.029.
2
Artificial intelligence-based prediction of organ involvement in Sjogren's syndrome using labial gland biopsy whole-slide images.基于人工智能利用唇腺活检全切片图像预测干燥综合征的器官受累情况。
Clin Rheumatol. 2025 Jun 5. doi: 10.1007/s10067-025-07518-5.
3
Perioperative management of caesarean section for a pregnant woman with Sjögren's disease and pulmonary embolism: a case report.患有干燥综合征和肺栓塞的孕妇剖宫产围手术期管理:一例病例报告
Front Cardiovasc Med. 2025 Apr 11;12:1467309. doi: 10.3389/fcvm.2025.1467309. eCollection 2025.
4
Trends in Initial Hospitalizations of Patients with Newly Diagnosed Sjogren's Disease in Poland Between 2012 and 2023: A Retrospective Data Analysis.2012年至2023年波兰新诊断干燥综合征患者的首次住院趋势:一项回顾性数据分析
J Clin Med. 2025 Mar 15;14(6):1999. doi: 10.3390/jcm14061999.
5
Higher Mortality Risk From Ovarian Carcinomas, Small Bowel Neoplasms, and B-Cell and Mucosa-Associated Lymphoid Tissue Lymphomas in Sjögren Syndrome Patients.干燥综合征患者患卵巢癌、小肠肿瘤以及B细胞和黏膜相关淋巴组织淋巴瘤的死亡风险更高。
J Clin Rheumatol. 2025 Mar 1;31(2):78-82. doi: 10.1097/RHU.0000000000002169. Epub 2024 Nov 15.
6
Salivary Flow Rate in Patients with Sjögren's Syndrome: Correlations with Salivary Gland Ultrasound Findings and Biomarkers of Disease Activity.干燥综合征患者的唾液流速:与唾液腺超声检查结果及疾病活动生物标志物的相关性
Int J Mol Sci. 2024 Dec 26;26(1):101. doi: 10.3390/ijms26010101.
7
Case report: Clinical and immunohistochemical manifestations of suspected Sjogren's disease in a dog.病例报告:一只犬疑似干燥综合征的临床及免疫组化表现
Front Vet Sci. 2024 Nov 27;11:1479363. doi: 10.3389/fvets.2024.1479363. eCollection 2024.
8
Establishment and evaluation of a risk prediction model for coronary heart disease in primary Sjögren's syndrome based on peripheral blood IL-6 and Treg percentages.基于外周血IL-6和调节性T细胞百分比的原发性干燥综合征冠心病风险预测模型的建立与评估
Front Immunol. 2024 Nov 27;15:1440370. doi: 10.3389/fimmu.2024.1440370. eCollection 2024.
9
Epidemiology of Sjogren's syndrome in a sample of the Egyptian population: a cross-sectional study.斯耶格伦综合征在埃及人群样本中的流行病学:一项横断面研究。
J Int Med Res. 2024 Oct;52(10):3000605241289292. doi: 10.1177/03000605241289292.
10
Vitamin D in Primary Sjogren's Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases.原发性干燥综合征(pSS)中的维生素D以及与pSS相关疾病发生相关的新型单核苷酸多态性的鉴定
Diagnostics (Basel). 2024 Sep 13;14(18):2035. doi: 10.3390/diagnostics14182035.

本文引用的文献

1
Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients.原发性干燥综合征的全身表现和死亡率:1045 例患者使用 EULAR-SS 疾病活动指数(ESSDAI)预测生存。
Ann Rheum Dis. 2016 Feb;75(2):348-55. doi: 10.1136/annrheumdis-2014-206418. Epub 2014 Nov 28.
2
Clinical course, prognosis, and cause of death in primary Sjögren's syndrome.原发性干燥综合征的临床病程、预后和死亡原因。
J Immunol Res. 2014;2014:647507. doi: 10.1155/2014/647507. Epub 2014 May 20.
3
Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis.原发性干燥综合征的流行病学:系统评价和荟萃分析。
Ann Rheum Dis. 2015 Nov;74(11):1983-9. doi: 10.1136/annrheumdis-2014-205375. Epub 2014 Jun 17.
4
Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.原发性干燥综合征患者淋巴瘤预测因素的识别:一项系统文献综述和荟萃分析
Rheumatol Int. 2015 Jan;35(1):17-26. doi: 10.1007/s00296-014-3051-x. Epub 2014 Jun 5.
5
Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality.原发性干燥综合征 1976-2005 年发病与相关间质性肺病:发病率和死亡率的基于人群研究。
BMJ Open. 2013 Nov 25;3(11):e003569. doi: 10.1136/bmjopen-2013-003569.
6
Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment.原发性干燥综合征中的恶性淋巴瘤:发病机制和治疗的最新进展。
Semin Arthritis Rheum. 2013 Oct;43(2):178-86. doi: 10.1016/j.semarthrit.2013.04.004. Epub 2013 Jun 29.
7
Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis.原发性干燥综合征与恶性肿瘤风险:系统评价和荟萃分析。
Ann Rheum Dis. 2014 Jun;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305. Epub 2013 May 17.
8
Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome.原发性干燥综合征中非霍奇金淋巴瘤的预后与转归
Medicine (Baltimore). 2012 Jan;91(1):1-9. doi: 10.1097/MD.0b013e31824125e4.
9
Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study.台湾地区原发性干燥综合征治疗后发病率和死亡率的一项基于人群的研究。
J Rheumatol. 2011 Apr;38(4):706-8. doi: 10.3899/jrheum.100883. Epub 2011 Jan 15.
10
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析的首选报告项目:PRISMA声明。
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. doi: 10.7326/0003-4819-151-4-200908180-00135. Epub 2009 Jul 20.

干燥综合征患者的死亡率、危险因素及病因:队列研究的系统评价与荟萃分析

Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.

作者信息

Singh Abha G, Singh Siddharth, Matteson Eric L

机构信息

Division of Rheumatology and.

Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Rheumatology (Oxford). 2016 Mar;55(3):450-60. doi: 10.1093/rheumatology/kev354. Epub 2015 Sep 27.

DOI:10.1093/rheumatology/kev354
PMID:26412810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5009445/
Abstract

OBJECTIVES

There is conflicting evidence regarding prognosis in patients with primary SS (pSS). The aim of this study was to estimate the rate, risk factors and causes of mortality in patients with pSS through a systematic review and meta-analysis.

METHODS

Through a systematic review of multiple databases through October 2014, we identified cohort studies reporting relative risk (compared with standardized population), risk factors and causes of mortality in patients with pSS. We estimated summary risk ratios (RRs) with 95% CIs using random effects model.

RESULTS

We identified 10 studies with 7888 patients (91% females) with pSS, of whom 682 patients died over a median average follow-up of 9 years. The pooled standardized mortality ratio in patients with pSS was 1.38 (95% CI 0.94, 2.01). Leading causes of mortality were cardiovascular diseases, solid-organ and lymphoid malignancies and infections; however, it is unclear whether these observed causes were overrepresented in patients with pSS as compared with the general population. Risk factors associated with increased mortality were advanced age at diagnosis [RR 1.09 (95% CI 1.07, 1.12)], male sex [RR 2.18 (95% CI 1.45, 3.27)], parotid enlargement [RR 1.81 (95% CI 1.02, 3.21)], abnormal parotid scintigraphy [RR 2.96 (95% CI 1.36, 6.45)], extraglandular involvement [RR 1.77 (95% CI 1.06, 2.95)], vasculitis [RR 7.27 (95% CI 2.70, 19.57)], anti-SSB positivity [RR 1.45 (95% CI 1.03, 2.04)], low C3 [RR 2.14 (95% CI 1.38, 3.32)] and C4 [RR 3.08 (95% CI 2.14, 4.42)] and cryoglobulinaemia [RR 2.62 (95% CI 1.77, 3.90)].

CONCLUSION

pSS is not associated with an increase in all-cause mortality as compared with the general population. However, a subset of patients with extraglandular involvement, vasculitis, hypocomplementaemia and cryoglobulinaemia may be at increased risk of mortality and require close follow-up.

摘要

目的

关于原发性干燥综合征(pSS)患者的预后存在相互矛盾的证据。本研究的目的是通过系统评价和荟萃分析来估计pSS患者的死亡率、危险因素及死亡原因。

方法

通过对截至2014年10月的多个数据库进行系统评价,我们确定了报告pSS患者相对风险(与标准化人群相比)、危险因素及死亡原因的队列研究。我们使用随机效应模型估计95%置信区间(CI)的汇总风险比(RRs)。

结果

我们确定了10项研究,共7888例pSS患者(91%为女性),其中682例患者在中位9年的随访期内死亡。pSS患者的汇总标准化死亡率为1.38(95%CI 0.94,2.01)。主要死亡原因是心血管疾病、实体器官和淋巴系统恶性肿瘤及感染;然而,与普通人群相比,这些观察到的原因在pSS患者中是否占比过高尚不清楚。与死亡率增加相关的危险因素包括诊断时年龄较大[RR 1.09(95%CI 1.07,1.12)]、男性[RR 2.18(95%CI 1.45,3.27)]、腮腺肿大[RR 1.81(95%CI 1.02,3.21)]、腮腺闪烁扫描异常[RR 2.96(95%CI 1.36,6.45)]、腺体外受累[RR 1.77(95%CI 1.06,2.95)]、血管炎[RR 7.27(95%CI 2.70,19.57)]、抗SSB阳性[RR 1.45(95%CI 1.03,2.04)]、低C3[RR 2.14(95%CI 1.38,3.32)]和C4[RR 3.08(95%CI 2.14,4.42)]以及冷球蛋白血症[RR 2.62(95%CI 1.77,3.90)]。

结论

与普通人群相比,pSS与全因死亡率增加无关。然而,一部分腺体外受累、血管炎、补体低下和冷球蛋白血症患者可能死亡风险增加,需要密切随访。